Vanderbilt University researchers have reported data on the discovery and development of a brain-penetrant, mGlu2 receptor negative allosteric modulator (NAM), VU-6066098, for the potential treatment of neurological and psychiatric disorders, including Alzheimer’s disease, depression and schizophrenia.